ROIV
Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$34.93
+1.51%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.5M | 8.3M | 29.1M | 32.7M | 31.5M |
| Cost of Revenue | 1.4M | 1.3M | 911.0K | 1.6M | 3.0M |
| Gross Profit | 6.1M | 7.0M | 28.1M | 31.1M | 28.5M |
| Operating Expenses | |||||
| R&D Expense | 730.9M | 681.8M | 550.4M | 439.9M | 454.1M |
| SG&A Expense | 642.0M | 610.5M | 591.4M | 416.1M | 383.4M |
| General & Admin Expense | 642.0M | 610.5M | 591.4M | 416.1M | 383.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (392.0K) | — | — | — | — |
| Total Operating Expenses | 1.4B | 1.3B | 1.1B | 856.0M | 837.5M |
| Cost and Expenses | 1.4B | 1.3B | 1.1B | 857.6M | 840.5M |
| Operating Income (EBIT) | (1.4B) | (1.3B) | (1.1B) | (824.9M) | (809.0M) |
| Non-Operating | |||||
| Interest Income | 166.7M | 178.1M | 258.4M | 146.4M | 32.2M |
| Interest Expense | — | — | — | 34.8M | 28.0M |
| Net Interest Income | 166.7M | 178.1M | 258.4M | 111.6M | 4.2M |
| Other Non-Op Income/Expense | 1.1B | 1.0B | 432.1M | 5.4B | (76.0M) |
| Non-Operating Income (excl Interest) | (1.1B) | (1.0B) | (432.1M) | (5.4B) | 48.0M |
| EBT (Pre-Tax Income) | (289.9M) | (264.6M) | (681.6M) | 4.6B | (885.0M) |
| Income Tax Expense | 124.7M | 133.3M | 48.2M | 21.5M | 4.1M |
| Bottom Line | |||||
| Net Income | (266.2M) | (299.8M) | (172.0M) | 4.3B | (1.0B) |
| Earnings from Cont. Ops | (414.6M) | (397.9M) | (729.8M) | 4.5B | (889.1M) |
| Earnings from Discont. Ops | — | — | 373.0M | (315.1M) | (226.4M) |
| Bottom Line Net Income | (266.2M) | (299.8M) | (172.0M) | 4.3B | (1.0B) |
| Per Share | |||||
| Basic EPS | ($0.38) | ($0.43) | ($0.24) | $5.55 | ($1.42) |
| Diluted EPS | ($0.44) | ($0.43) | ($0.24) | $5.23 | ($1.42) |
| Revenue Per Share | $0.01 | $0.01 | $0.04 | $0.04 | $0.04 |
| Shares | |||||
| Basic Shares Outstanding | 720.8M | 693.9M | 725.4M | 783.2M | 712.8M |
| Diluted Shares Outstanding | 720.8M | 693.9M | 725.4M | 831.0M | 712.8M |
| Profitability Metrics | |||||
| EBITDA | (281.3M) | (261.2M) | (667.5M) | 4.6B | (838.2M) |
| D&A | 8.5M | 3.3M | 14.1M | 22.0M | 18.9M |
| EBIT | (289.9M) | (264.6M) | (681.6M) | 4.6B | (857.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026